BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 27578122)

  • 1. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.
    Maki KC; Guyton JR; Orringer CE; Hamilton-Craig I; Alexander DD; Davidson MH
    J Clin Lipidol; 2016; 10(4):905-914. PubMed ID: 27578122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
    Toth PP; Zarotsky V; Sullivan JM; Laitinen D
    Curr Med Res Opin; 2009 Jun; 25(6):1355-63. PubMed ID: 19425901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertriglyceridemia and cardiovascular risk reduction.
    Jacobson TA; Miller M; Schaefer EJ
    Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do triglyceride-lowering drugs decrease risk of cardiovascular disease?
    Maki KC; Dicklin MR
    Curr Opin Lipidol; 2017 Aug; 28(4):374-379. PubMed ID: 28441155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
    Preston Mason R
    Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
    Mozaffarian D; Maki KC; Bays HE; Aguilera F; Gould G; Hegele RA; Moriarty PM; Robinson JG; Shi P; Tur JF; Lapointe JF; Aziz S; Lemieux P;
    JAMA Netw Open; 2022 Jan; 5(1):e2141898. PubMed ID: 34989797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.
    Bays H
    Drugs Today (Barc); 2008 Mar; 44(3):205-46. PubMed ID: 18536782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Icosapent ethyl for the treatment of hypertriglyceridemia.
    Ballantyne CM; Braeckman RA; Soni PN
    Expert Opin Pharmacother; 2013 Jul; 14(10):1409-16. PubMed ID: 23701295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hypertriglyceridemia in the diabetic patient.
    Jialal I; Amess W; Kaur M
    Curr Diab Rep; 2010 Aug; 10(4):316-20. PubMed ID: 20532703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.
    Tenenbaum A; Klempfner R; Fisman EZ
    Cardiovasc Diabetol; 2014 Dec; 13():159. PubMed ID: 25471221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol.
    Szapary PO; Rader DJ
    Curr Opin Pharmacol; 2001 Apr; 1(2):113-20. PubMed ID: 11714084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
    J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
    Bays HE; Tighe AP; Sadovsky R; Davidson MH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertriglyceridemia: the importance of identifying patients at risk.
    Kushner PA; Cobble ME
    Postgrad Med; 2016 Nov; 128(8):848-858. PubMed ID: 27710158
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.